1. Moving Evidence into Practice: Breast Cancer Highlights From Chicago

2. This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. I-SPY 2 Study

4. I-SPY 2 TRIAL Schema: HER2- Signatures

5. Pembrolizumab Graduated in All HER2- Signatures: Both HR+/HER2- and TNBC

6. Select Treatment-Related Adverse Events

7. AEs of Special Interest (Including Immune-Related Toxicities)

8. Primary and Secondary Adrenal Insufficiency

9. Conclusions

10. MONARCH 2 Phase 3 Trial

11. MONARCH 2 Results

12. Abemaciclib for Treatment of Brain Metastases

13. MONALEESA-2 Phase 3 Trial: Second Interim Analysis

14. PALOMA-1 Study

15. OlympiAD Trial

16. OlympiAD Trial: Results

17. Brightness Study

18. Brightness Efficacy Results

19. ABRAZO Phase 2 Clinical Trial: Key Eligibility Criteria

20. Primary Efficacy Endpoint: Talazoparib ORR by Independent Radiologist Facility

21. APHINITY Trial

22. APHINITY Results

23. Results of Subgroup Analysis of IDFS at 4 Years

24. Safety Profile

25. APT Trial

26. Updated Analysis of APT Trial

27. Abbreviations

28. Abbreviations (cont)